Clinical Study Confirms Lubrizol MAGSHAPE™ Enhances Magnesium Absorption
Lubrizol’s MAGSHAPE™ microcapsules, a micronized and microencapsulated form of magnesium, have been found to significantly improve magnesium absorption compared to other commonly used magnesium sources, according to a recent study published in Nutrients. The study was conducted by researchers at Bionos Biotech SL and Lubrizol Nutraceuticals.
The study demonstrated superior bioavailability and reduced side effects for this innovative magnesium solution, which was specifically developed for people seeking scientifically backed magnesium supplements. These findings align with results from a recent consumer study, where participants preferred the taste and texture of MAGSHAPE™ microcapsules over magnesium from four other commonly used options.
The clinical study was a double-blind, randomized, crossover trial involving 40 healthy volunteers. These participants were given various magnesium supplements under controlled conditions. The primary goal of the study was to evaluate the magnesium (Mg) levels in blood plasma following oral intake of MAGSHAPE™ microcapsules, compared with other forms of magnesium, including magnesium oxide, magnesium citrate, and magnesium bisglycinate. Blood samples were collected at baseline, one hour, four hours, and six hours after consumption of each magnesium product. A secondary objective was to assess the occurrence of side effects commonly associated with magnesium supplementation.
The results revealed that MAGSHAPE™ microcapsules increased blood plasma magnesium levels at all time points measured after the baseline. The microencapsulation technology of MAGSHAPE™ also enabled a sustained increase in blood plasma magnesium levels, with elevated levels maintained for up to six hours post-ingestion. Participants reported fewer adverse effects, such as intestinal motility and gastric discomfort, with MAGSHAPE™ microcapsules compared to the other magnesium forms included in the study.
“These findings highlight the potential of MAGSHAPE™ microcapsules to transform magnesium supplementation,” said Isabel Gomez, Marketing Manager at Lubrizol Nutraceuticals. “The study compared MAGSHAPE microencapsulated magnesium oxide with raw magnesium oxide, showing that the enhanced absorption and reduced side effects observed can be attributed to the innovative microencapsulation technology used in MAGSHAPE™.”
Based on the increased blood plasma magnesium levels observed in the study, the researchers suggest that this new magnesium solution could benefit individuals who aim to maintain optimal magnesium levels for overall health, muscle recovery, and sleep improvement.
“The sustained increase in blood plasma magnesium levels and the gastric tolerability reported by participants make MAGSHAPE™ an excellent choice for those seeking the health benefits of maintaining adequate magnesium levels,” said Teresa Negra, New Business Development Specialist at Lubrizol Nutraceuticals.
Alan Connolly, R&D Manager at Lubrizol Nutraceuticals, added, “This innovative solution shows great promise for individuals looking to optimize magnesium intake for muscle recovery and to support healthy sleep patterns. The combination of increased absorption and reduced side effects makes MAGSHAPE™ a strong contender in the magnesium supplement market.”
In the clinical trial, participants reported fewer gastrointestinal issues like bloating, cramping, and discomfort, which are common side effects of many magnesium supplements. These findings suggest that MAGSHAPE™ could be a more tolerable alternative for those who have experienced discomfort with other magnesium products.
Lubrizol’s development of MAGSHAPE™ microencapsulation technology is a breakthrough in magnesium supplementation, as it addresses both absorption efficiency and gastrointestinal tolerance. The study results provide a solid scientific foundation for the effectiveness and safety of MAGSHAPE™ microcapsules, making it an ideal solution for people who need to support their magnesium intake for various health benefits.
MAGSHAPE™ is especially suitable for people with higher magnesium needs, such as athletes, individuals experiencing sleep disturbances, and those managing muscle cramps. The unique microencapsulation process ensures that magnesium is delivered more effectively to the body, where it can be utilized for optimal health outcomes.
To learn more about MAGSHAPE™, request a sample, or explore further details, visit Lubrizol’s website.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a science-driven company specializing in sustainable chemistry solutions that advance mobility, enhance well-being, and power modern living. Lubrizol’s innovations focus on delivering value at the intersection of science, market needs, and commercial success. Founded in 1928, the company has a global presence with over 100 manufacturing facilities, sales and technical offices, and nearly 8,000 employees worldwide.
